Delta-10 THC

Delta-9-tetrahydrocannabinol (Delta-9 THC) is the principal intoxicating compound in the Cannabis sativa plant, responsible for the characteristic "high" associated with marijuana use. It forms when THCA, its acidic precursor, undergoes decarboxylation through heat, light, or extended storage. THC is one of over 100 identified cannabinoids and occurs in the plant's resin-producing trichomes, concentrated most heavily in flower. Legally, the compound is defined by concentration thresholds rather than chemical identity alone — the same molecule is classified differently depending on the THC percentage of the source material.

Legal: Under the 2018 Farm Bill, hemp is defined as cannabis containing no more than 0.3% Delta-9 THC by dry weight; above that threshold, the plant is legally "marijuana," a Schedule I substance under federal law. Hemp-derived products at or below 0.3% Delta-9 THC are federally legal, though many states impose their own limits, total-THC caps, or outright restrictions on intoxicating hemp products — always check the state matrix before selling or shipping.

Market: Delta-9 THC is the dominant cannabinoid in flower, pre-rolls, vape cartridges, and traditional dispensary concentrates, and increasingly appears in hemp-derived beverages, gummies, and tinctures formulated to stay under the 0.3% dry-weight threshold. Certificates of analysis (COAs) from third-party labs report Delta-9 THC and total THC (accounting for THCA conversion) separately — buyers and retailers should check both figures, not just one.

What's the difference between Delta-9 THC and "total THC" on a lab report? Delta-9 THC on a COA measures only the already-active form present in the sample. "Total THC" adds a conversion factor for THCA (roughly 0.877), estimating how much THC would exist after decarboxylation, such as smoking or vaping. Total THC is the figure most state hemp-compliance limits actually reference.

Tetrahydrocannabinolic acid (THCA) is the raw, acidic precursor to Delta-9 THC, synthesized directly by the cannabis plant and present in freshly harvested flower in far greater quantity than THC itself. THCA converts to Delta-9 THC through decarboxylation — a chemical reaction triggered by heat, such as smoking, vaping, or cooking, or by prolonged light and air exposure. Because raw THCA is not intoxicating, it occupies a legal gray area: flower can test compliant as "hemp" by Delta-9 THC content alone while carrying THCA levels that convert well past that threshold once heated.

Legal: THCA itself is not scheduled by name federally, and the 2018 Farm Bill's 0.3% threshold applies only to Delta-9 THC measured at time of testing, not total post-conversion THC. This has enabled "high-THCA" hemp flower marketed as federally compliant despite converting to well over 0.3% THC when smoked. Several states have moved to close this gap by requiring total-THC testing instead — state rules vary significantly, so always check the state matrix.

Market: THCA is the dominant cannabinoid in raw, unheated hemp and cannabis flower, and "THCA flower" or "THCA pre-rolls" are sold widely in hemp retail channels distinct from traditional dispensaries. Lab COAs should list THCA, Delta-9 THC, and calculated total THC as separate line items; buyers relying on flower for smoking should review total THC, not just the Delta-9 figure, to understand actual post-combustion potency.

Is THCA flower actually legal if it converts to THC when smoked? It depends on the testing method a jurisdiction requires. Products testing compliant under a Delta-9-only standard may fail a total-THC standard measuring post-conversion potency. Federal guidance and state laws are inconsistent on this point, and enforcement approaches differ — check the current rules for the specific state before purchase or sale.

Cannabidiol (CBD) is the second-most abundant cannabinoid in cannabis and the most commercially prevalent non-intoxicating compound derived from the plant. It forms when its acidic precursor, CBDA, decarboxylates under heat or aging. CBD is found in both hemp and marijuana cultivars, though hemp is typically bred to maximize CBD while minimizing THC. It does not bind strongly to the CB1 receptors responsible for THC's intoxicating effects, which is why it is broadly marketed as a non-psychoactive alternative across wellness and consumer product categories.

Legal: Hemp-derived CBD (from cannabis containing 0.3% or less Delta-9 THC by dry weight) was federally legalized by the 2018 Farm Bill. CBD derived from marijuana remains a Schedule I substance federally regardless of the CBD itself. The FDA has not approved most CBD consumer products and restricts certain health claims and food/beverage additions; state rules on CBD in food, cosmetics, and retail sale vary — check the state matrix.

Market: CBD appears across nearly every product format: tinctures, capsules, topicals, gummies, beverages, vapes, and pet products. It is the most heavily third-party-tested cannabinoid, and COAs typically report CBD content alongside THC to confirm hemp-compliance. Labeling accuracy is a persistent market issue — independent testing has repeatedly found products with actual CBD content differing significantly from label claims, so verifying batch-specific COAs matters.

Will CBD show up on a drug test? Pure CBD typically does not trigger standard THC drug screens, but many CBD products contain trace THC (up to the legal 0.3% hemp threshold or from cross-contamination), which can accumulate with regular use. Broad-spectrum or isolate products are formulated to remove THC; full-spectrum products are not. Check the COA for THC content.

Cannabidiolic acid (CBDA) is the raw, acidic precursor to CBD, produced directly by the cannabis plant's glandular trichomes alongside THCA. It is the dominant cannabinoid in raw, unheated hemp biomass before any processing occurs. CBDA converts to CBD through decarboxylation, the same heat- or time-driven reaction that converts THCA to THC, meaning fresh, undried hemp material is chemically distinct from the cured or heated products most consumers encounter. CBDA is structurally and functionally separate from THCA and does not convert into any form of THC.

Legal: CBDA is not a controlled substance federally and is generally treated the same as CBD under the 2018 Farm Bill's hemp definition, since it poses no THC-conversion concern. Products derived from hemp containing 0.3% or less Delta-9 THC by dry weight are federally legal; CBDA content itself does not affect that calculation. As with other hemp cannabinoids, marketing and sale rules differ by state — check the state matrix.

Market: CBDA appears primarily in raw hemp juice, raw tinctures, and cold-processed extracts marketed as retaining the plant's unheated chemical profile, since standard decarboxylation (drying, curing, heating) converts it to CBD. It is less common than CBD in finished consumer goods because most extraction and manufacturing processes intentionally decarboxylate. COAs for raw or "live" products should list CBDA as a distinct line item from CBD.

Is CBDA the same thing as CBD? No. CBDA is the acidic form the plant produces naturally; CBD is what results after decarboxylation removes a carboxyl group, typically via heat. They are chemically distinct compounds with different molecular structures, though one converts into the other. A raw juice and a heated tincture can have very different CBDA-to-CBD ratios.

Cannabigerol (CBG) is often called a "parent" cannabinoid because its acidic form, CBGA, is the biosynthetic precursor that plant enzymes convert into THCA, CBDA, and CBCA before those in turn become THC, CBD, and CBC. By the time most cannabis plants reach maturity, enzymes have converted nearly all CBGA into other cannabinoids, leaving only trace CBG — which is why specialty hemp cultivars are bred to harvest early or suppress conversion enzymes to yield higher CBG concentrations. It is non-intoxicating and typically present at under 1% in standard flower.

Legal: CBG is not federally scheduled by name. Hemp-derived CBG products, from plants at or below 0.3% Delta-9 THC by dry weight, fall under the 2018 Farm Bill's hemp definition and are federally legal. Because CBG-dominant cultivars are still hemp-derived cannabis, the same state-level restrictions that apply to other hemp cannabinoids can apply to CBG products — rules on sale, age restriction, and product form vary by state; check the state matrix.

Market: CBG appears in tinctures, capsules, isolate powders, and increasingly in "CBG flower" bred from specialty low-THC, high-CBG cultivars. Because natural CBG yields are low, many products use isolate or distillate to reach labeled concentrations, so COAs should confirm CBG content matches the label rather than relying on "full-spectrum" framing alone. It is frequently sold as a component in multi-cannabinoid blends rather than standalone.

Why is CBG more expensive than CBD? Mature cannabis plants convert most CBGA into other cannabinoids before harvest, so natural CBG yields are low. Producing meaningful CBG concentrations requires early harvesting, specially bred cultivars, or isolating it during extraction — all of which add cost compared to CBD, which cannabis plants generally produce in much higher natural quantities.

Cannabigerolic acid (CBGA) is the first cannabinoid the cannabis plant synthesizes and is widely regarded as the biochemical origin point for the entire cannabinoid family. Specific synthase enzymes convert CBGA into THCA, CBDA, or CBCA depending on the plant's genetics, after which those acids may further decarboxylate into THC, CBD, and CBC respectively. In most mature plants, CBGA is almost fully converted and present only in trace amounts; young plants and certain bred cultivars retain higher CBGA levels, which is the basis for CBGA- and CBG-focused hemp products.

Legal: CBGA carries the same federal treatment as other non-THC hemp cannabinoids: products derived from cannabis at or below 0.3% Delta-9 THC by dry weight qualify as hemp under the 2018 Farm Bill and are federally legal. CBGA itself is not scheduled. Because CBGA is chemically upstream of THCA, some raw or "live" hemp products emphasize CBGA content in marketing — state labeling and sale rules still apply and vary; check the state matrix.

Market: CBGA is found mainly in raw or "live resin" style extracts, raw hemp juices, and young-plant harvests marketed to preserve the acidic cannabinoid profile before decarboxylation. It is far less common in finished consumer goods than CBGA's downstream products, CBD and CBG, since most manufacturing intentionally decarboxylates. COAs for raw or unheated products should report CBGA separately from CBG and from CBGA's other downstream acids.

Why is CBGA called the "mother cannabinoid"? Because plant enzymes synthesize CBGA first, then convert it into the acidic precursors of THC, CBD, and CBC (THCA, CBDA, and CBCA). Nearly every other cannabinoid in the plant traces back to CBGA as its biochemical starting point, which is why it is described that way in scientific literature.

Cannabinol (CBN) is not synthesized directly by the plant's enzymes in meaningful quantity; instead, it forms primarily as a degradation product when THC is exposed to oxygen, heat, and light over time, such as in aged or improperly stored cannabis. Its acidic precursor, CBNA, results from the oxidation of THCA. Because CBN accumulates as cannabis ages, older or heat-stressed flower typically shows higher CBN and lower THC content, and CBN concentration is sometimes used informally as a rough indicator of product age or storage conditions.

Legal: CBN is not scheduled by name federally. Because CBN derives from THC degradation, hemp-compliance testing generally still centers on Delta-9 THC and total THC content rather than CBN specifically, though CBN itself does not count toward those thresholds. Hemp-derived CBN products (from source material at or below 0.3% Delta-9 THC) are federally legal under the 2018 Farm Bill; state treatment of hemp cannabinoids varies — check the state matrix.

Market: CBN is widely marketed in "sleep" and "nighttime" product lines — tinctures, gummies, and capsules, often blended with CBD or melatonin — reflecting reported use patterns among consumers seeking evening formulations, without implying an established sedative mechanism. Because natural CBN yields are low, most CBN in commercial products is isolate added intentionally rather than aged-in. COAs should confirm CBN content, since underdosed "sleep blends" have been identified in testing.

Does old, stale weed have more CBN? Yes, generally. CBN forms as THC degrades from exposure to oxygen, light, and heat over time, so improperly stored or aged cannabis tends to show elevated CBN and reduced THC on lab testing. This is a widely cited chemical relationship, distinct from any claim about what that shift does for the consumer.

Cannabichromene (CBC) is one of the four major original cannabinoids alongside THC, CBD, and CBG, formed when its acidic precursor CBCA — itself derived from CBGA — undergoes decarboxylation. CBC is typically present in cannabis at low concentrations compared to THC and CBD, and its levels vary significantly by cultivar and growing conditions. It does not produce intoxication and is one of the lesser-studied major cannabinoids relative to THC and CBD, with a smaller body of available research and less standardized commercial testing infrastructure.

Legal: CBC is not scheduled by name federally. Hemp-derived CBC products, sourced from cannabis at or below 0.3% Delta-9 THC by dry weight, fall within the 2018 Farm Bill's hemp definition and are federally legal. Because CBC is a minor cannabinoid, it is less frequently the subject of state-specific rulemaking than THC, CBD, or Delta-8, but it remains subject to whatever general hemp-cannabinoid restrictions a state has adopted — check the state matrix.

Market: CBC appears mainly as a minor component in full-spectrum extracts, tinctures, and "entourage"-marketed blends rather than as a standalone product, since isolated CBC is less commercially available than CBD or CBG isolate. Because concentrations are naturally low, CBC is not always itemized on every COA — buyers wanting confirmed CBC content should look for labs that report a full minor-cannabinoid panel rather than a THC/CBD-only test.

Why isn't CBC as well known as CBD or THC? CBC occurs in much smaller concentrations in most cannabis cultivars than THC or CBD, making it harder and more expensive to isolate at scale. Research volume and commercial infrastructure have concentrated around the higher-yield cannabinoids first, so CBC-specific literature and standardized testing remain comparatively limited.

Tetrahydrocannabivarin (THCV) is a propyl-chain homolog of THC — chemically similar but built on a shorter carbon side chain — that forms from decarboxylation of its acidic precursor, THCVA. It occurs naturally in certain cannabis landrace strains, notably African sativa varieties, generally at low concentrations relative to THC. THCV's pharmacological behavior is reported to differ from Delta-9 THC's, including different receptor-binding characteristics at varying doses, though the compound is markedly less studied and less commercially standardized than the major cannabinoids.

Legal: THCV is not scheduled by name federally. Because THCV is structurally a THC analog but distinct from Delta-9 THC, hemp-compliance testing for it can be inconsistent across labs and states, and its psychoactive potential has drawn regulatory scrutiny in some jurisdictions similar to other minor THC isomers. Hemp-derived THCV products (from source material at or below 0.3% Delta-9 THC by dry weight) are generally treated as legal under the 2018 Farm Bill — check the state matrix, as treatment varies.

Market: THCV appears in tinctures, capsules, and vape formulations, frequently marketed toward consumers interested in its reportedly distinct effect profile compared to Delta-9 THC, without therapeutic claims attached. Because natural THCV-dominant cultivars are rare, many products rely on isolate to reach labeled potency. Given limited standardization, buyers should confirm THCV is separately itemized on the COA rather than folded into a generic "other cannabinoids" total.

Is THCV the same as regular THC? No. THCV shares a similar chemical backbone to Delta-9 THC but has a shorter side chain, which changes how it interacts with the body's receptors. It is reported to produce different effects at different doses than Delta-9 THC, though it remains far less studied and less widely available in consistent, standardized form.

Delta-8-tetrahydrocannabinol (Delta-8 THC) is a THC isomer that occurs naturally in cannabis only in trace amounts, so nearly all commercial Delta-8 is produced by chemically converting hemp-derived CBD through an acid-catalyzed isomerization process rather than extracted directly from the plant. This synthesis route distinguishes it from Delta-9 THC and CBD, which are typically extracted natively. Delta-8 shares Delta-9 THC's basic double-bond ring structure with the bond positioned differently, which is reported to produce intoxicating effects generally described as milder or different in character than Delta-9 THC.

Legal: Delta-8's legal status is contested. Proponents argue hemp-derived Delta-8 is federally legal under the 2018 Farm Bill because it is derived from compliant, low-Delta-9-THC hemp; the DEA and some courts have taken the position that synthetically converted cannabinoids fall outside the hemp exemption. A patchwork of states have banned, restricted, or explicitly regulated Delta-8 as an intoxicating hemp product. This is an actively shifting area — check the state matrix and do not assume federal legality implies state legality.

Market: Delta-8 THC is widely sold in vape cartridges, gummies, tinctures, and pre-rolls, largely through hemp and smoke-shop retail channels outside licensed dispensary systems. Because it is manufactured via chemical conversion rather than natural extraction, product quality and residual-solvent or reaction-byproduct contamination have been documented concerns in independent testing; COAs from accredited third-party labs covering full-panel contaminant and byproduct screening — not just potency — are especially important for this compound.

Is Delta-8 THC natural or synthetic? Delta-8 THC does occur naturally in the plant, but only in trace amounts. Virtually all Delta-8 sold commercially is manufactured by chemically converting hemp-derived CBD in a lab process, which is why it is often described as semi-synthetic. This manufacturing step is central to ongoing legal and quality-control debates about the compound.

Delta-10-tetrahydrocannabinol (Delta-10 THC) is another positional isomer of THC, occurring in the plant in only negligible natural amounts and produced commercially through chemical conversion of hemp-derived CBD, similar in concept to Delta-8 production but yielding a different double-bond position on the molecule. It emerged in the hemp market more recently than Delta-8 and is generally described in user and market reporting as producing milder intoxicating effects than Delta-9 THC, with a subjective character reported as distinct from Delta-8 as well, though it remains one of the least-researched THC isomers in commercial circulation.

Legal: Delta-10's legal status mirrors the Delta-8 dispute: it is marketed as hemp-derived and federally legal under the 2018 Farm Bill by proponents, while federal agencies and some state regulators treat chemically synthesized cannabinoids as falling outside the hemp exemption regardless of starting material. Many of the same states restricting Delta-8 also restrict or ban Delta-10. Given the unsettled and evolving regulatory landscape, check the state matrix before any sale or distribution.

Market: Delta-10 THC is sold in vapes, gummies, and pre-rolls, often positioned alongside or blended with Delta-8 in hemp and smoke-shop retail. Because production involves chemical isomerization at commercial scale, and because Delta-10 is a smaller, newer market than Delta-8, testing infrastructure and manufacturing consistency are less mature; buyers should prioritize COAs that screen for isomerization byproducts and residual reaction chemicals, not just labeled potency.

How is Delta-10 different from Delta-8? Both are THC isomers manufactured mainly by chemically converting hemp-derived CBD, but the double bond sits in a different position on the molecule for each. Consumer and market reporting commonly describes their subjective effects as different from one another and from Delta-9 THC, though these are user characterizations, not clinical findings.

Tetrahydrocannabiphorol (THCP) is a naturally occurring cannabinoid first identified in cannabis by Italian researchers in 2019, distinguished from Delta-9 THC by a longer seven-carbon side chain instead of THC's five-carbon chain. Natural THCP concentrations in the plant are extremely low, so virtually all commercial THCP is produced through laboratory synthesis rather than plant extraction. Preliminary research reported markedly higher binding affinity for the body's CB1 receptor compared to Delta-9 THC, which the market has interpreted as indicating substantially greater potency, though this remains an early and limited body of research.

Legal: THCP is not scheduled by name federally, and hemp-derived THCP is marketed as compliant under the 2018 Farm Bill when sourced from hemp at or below 0.3% Delta-9 THC. Because commercial THCP is lab-synthesized rather than plant-extracted, it faces the same "synthetic derivative" legal exposure as Delta-8 and Delta-10 in jurisdictions and under federal interpretations that exclude chemically converted cannabinoids from the hemp exemption. Treatment varies significantly by state — check the state matrix.

Market: THCP appears mainly in vape cartridges, concentrates, and gummies, frequently blended with Delta-8, Delta-9, or Delta-10 THC and marketed on claimed potency due to its reported CB1-binding affinity. Because it is a newer, lab-synthesized novel cannabinoid with limited standardized testing history, contaminant and byproduct screening on the COA — beyond simple potency listing — is particularly important for THCP-containing products.

Is THCP stronger than regular THC? Early laboratory research reported that THCP binds to the CB1 receptor with notably higher affinity than Delta-9 THC in vitro, which the market has translated into "more potent" marketing claims. However, receptor-binding affinity alone does not directly equate to real-world dosed effect, and independent, large-scale human research on THCP remains limited.

Hexahydrocannabinol (HHC) is a hydrogenated form of THC — produced by adding hydrogen atoms to the THC molecule in a process chemically similar to converting vegetable oil into margarine — which eliminates the double bond that defines THC's structure. Trace natural HHC has been reported in cannabis pollen and seeds, but essentially all commercial HHC is manufactured by hydrogenating hemp-derived THC or CBD in a lab. Synthesis produces a mix of two isomer forms (9R and 9S) with reportedly different potency, and manufacturers rarely disclose the ratio.

Legal: HHC's legal status is disputed on similar grounds to Delta-8: it is not scheduled by name, and proponents market it as a hemp derivative legal under the 2018 Farm Bill, while federal and some state authorities argue lab-synthesized cannabinoids fall outside the hemp exemption regardless of the hemp starting material. A growing number of states have explicitly banned or restricted HHC. Regulatory posture continues to shift — check the state matrix before any sale.

Market: HHC is sold in vapes, gummies, and concentrates through hemp and smoke-shop retail channels, often marketed on claims of THC-like effects with greater oxidative stability and a longer shelf life than THC. Because the hydrogenation process and catalyst residues (sometimes involving metal catalysts) are less standardized industry-wide, COAs screening for residual catalysts and reaction byproducts, not just cannabinoid potency, are particularly relevant for HHC products.

Is HHC the same thing as THC? No. HHC is a hydrogenated derivative — THC with hydrogen atoms added and its defining double bond removed — which makes it a chemically distinct molecule, not THC itself. It is typically produced from hemp-derived THC or CBD through a lab hydrogenation process rather than occurring naturally in meaningful quantity.

Cannabidivarin (CBDV) is a propyl-chain homolog of CBD, structurally related in the same way THCV relates to THC, formed from decarboxylation of its acidic precursor CBDVA. It occurs naturally at meaningful concentrations mainly in certain landrace cannabis and hemp varieties, notably some indica-leaning strains from regions such as Asia, though it is present only as a minor cannabinoid in most commercial cultivars. CBDV does not produce intoxication and has drawn scientific research interest, though it remains far less commercially developed than CBD.

Legal: CBDV is not scheduled by name federally. Hemp-derived CBDV products, from source material at or below 0.3% Delta-9 THC by dry weight, fall under the 2018 Farm Bill's hemp definition and are federally legal, following the same framework as CBD and CBG. Because CBDV is a minor, low-volume cannabinoid, state-specific rulemaking targeting it specifically is uncommon, but general hemp-product regulations still apply — check the state matrix.

Market: CBDV is a niche cannabinoid, appearing mainly in specialty tinctures and minor-cannabinoid blends marketed to consumers seeking a broader cannabinoid profile, rather than as a mainstream standalone product. Commercial availability and isolate supply are limited compared to CBD or CBG. Because it is uncommon, COAs should be checked to confirm CBDV is actually present and quantified rather than assumed from "full-spectrum" labeling alone.

How is CBDV different from CBD? CBDV has a shorter carbon side chain than CBD — a propyl chain instead of CBD's pentyl chain — the same structural difference that separates THCV from THC. This changes its molecular weight and chemical behavior. CBDV is non-intoxicating like CBD but is naturally far less abundant in most cannabis and hemp cultivars.

Terpenes are aromatic hydrocarbon compounds produced in the same glandular trichomes that produce cannabinoids, responsible for cannabis's characteristic smell and flavor — notes like citrus, pine, diesel, or lavender all trace back to specific terpenes such as limonene, pinene, myrcene, or linalool. Terpenes are not unique to cannabis; the same or closely related compounds occur widely across plants, fruits, and herbs. A cultivar's terpene profile is distinct from its cannabinoid profile and is commonly used in marketing and product differentiation to describe aroma, flavor, and general product character rather than potency.

Legal: Terpenes themselves are not controlled substances and are not subject to THC-based hemp thresholds; they are legal regardless of source, including terpenes isolated from non-cannabis plants and added back into cannabis products. Some states regulate "total terpene content" or require terpene disclosure on labels as part of general product-labeling rules rather than controlled-substance law. As with all hemp and cannabis product formulation rules, check the state matrix for specific labeling requirements.

Market: Terpenes are sold as standalone flavoring additives and are also reintroduced into vape cartridges, concentrates, and edibles after processing strips the plant's natural terpenes — a practice sometimes disclosed as "terpene-infused" or "botanically derived terpenes." COAs increasingly include terpene panels alongside cannabinoid potency, and total terpene percentage is often used in marketing as a proxy for aroma intensity or product quality, though the two are not strictly interchangeable claims.

Do terpenes affect how a cannabis product feels, or just how it tastes and smells? Terpenes are best documented as aroma and flavor compounds. Some industry and early research discussion proposes terpenes may influence overall product character alongside cannabinoids — often called the "entourage effect" — but this remains a debated and not firmly established idea, and terpenes are not marketed here as producing any specific effect.